Colonial River Wealth Management LLC Has $295,000 Holdings in Merck & Co., Inc. (NYSE:MRK)

Colonial River Wealth Management LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 11.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,792 shares of the company’s stock after buying an additional 401 shares during the quarter. Colonial River Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $295,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Cowen Prime Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $31,000. PARK CIRCLE Co raised its stake in Merck & Co., Inc. by 100.0% in the 2nd quarter. PARK CIRCLE Co now owns 400 shares of the company’s stock valued at $31,000 after acquiring an additional 200 shares during the period. AlphaMark Advisors LLC bought a new stake in Merck & Co., Inc. in the 2nd quarter valued at $39,000. Lake Point Wealth Management bought a new stake in Merck & Co., Inc. in the 2nd quarter valued at $40,000. Finally, Monumental Financial Group Inc. bought a new stake in Merck & Co., Inc. in the 2nd quarter valued at $44,000. 71.83% of the stock is owned by institutional investors.

A number of research firms recently weighed in on MRK. Berenberg Bank restated a “hold” rating and issued a $92.00 price target (up previously from $86.00) on shares of Merck & Co., Inc. in a research note on Sunday. Truist initiated coverage on Merck & Co., Inc. in a research report on Tuesday, July 27th. They set a “buy” rating and a $92.00 price objective on the stock. Truist Securities initiated coverage on Merck & Co., Inc. in a research report on Tuesday, July 27th. They set a “buy” rating and a $76.79 price objective on the stock. Mizuho initiated coverage on Merck & Co., Inc. in a research report on Friday, October 1st. They set a “buy” rating and a $100.00 price objective on the stock. Finally, Morgan Stanley increased their price objective on Merck & Co., Inc. from $85.00 to $88.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $92.18.

NYSE:MRK traded up $0.54 during trading hours on Thursday, hitting $79.49. The company’s stock had a trading volume of 182,854 shares, compared to its average volume of 12,310,182. The stock has a fifty day simple moving average of $76.31 and a 200-day simple moving average of $76.75. The company has a market capitalization of $201.22 billion, a P/E ratio of 36.08, a PEG ratio of 2.16 and a beta of 0.41. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.31 and a quick ratio of 1.06. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $85.60.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Wednesday, July 28th. The company reported $1.31 earnings per share for the quarter, meeting the consensus estimate of $1.31. The business had revenue of $11.40 billion for the quarter, compared to analyst estimates of $11.21 billion. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. During the same period last year, the firm posted $1.37 earnings per share. On average, equities analysts predict that Merck & Co., Inc. will post 5.51 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 7th. Investors of record on Wednesday, September 15th were paid a $0.65 dividend. This represents a $2.60 annualized dividend and a yield of 3.27%. The ex-dividend date of this dividend was Tuesday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 43.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Article: What is the QQQ ETF?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.